Long-Acting Amylin Analog
Amylin receptor agonist. Studied alongside GLP-1 compounds in metabolic models.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a pancreatic peptide that reduces appetite and slows gastric emptying through central nervous system pathways distinct from GLP-1. Combined with semaglutide (CagriSema), it demonstrated up to 22.7% weight reduction in phase 2 trials.
Store lyophilized at -20°C. Reconstituted: refrigerate 2–8°C, use within 4–6 weeks.